Major Depressive Disorder (MDD) is a debilitating and chronic illness which is characterised across a broad spectrum of emotional and physical symptoms.

Most notable amongst these symptoms are a persistent low mood, a preoccupation with thoughts and feelings of worthlessness, unwarranted guilt, helplessness and an inability to experience genuine pleasure in activities that were formerly enjoyed.

Despite the availability of numerous treatments, those who are suffering with depression are usually treated with a marketed antidepressant therapy. However, not all patients respond sufficiently to this. Currently, MAC Clinical Research is looking into a new treatment for depression with the aim of achieving consistent and improved long term results.

The medication being investigated by MAC Clinical Research, as a possible treatment for MDD, stimulates the brain’s dopamine system which is typically associated with feelings of happiness and pleasure.

The trial being conducted at MAC Clinical Research’s Yorkshire site, based in Leeds, will assess whether combining the trial medication with a marketed antidepressant treatment can improve the symptoms of depression, in patients who have an inadequate response to their current antidepressant treatment.

This ethically approved trial will last nine months with a total of 16 visits, where you will be seen by a psychiatrist and dedicated clinical team. Your progress will be monitored using clinical assessments and you will be prescribed medication at each visit.

Participation is voluntary and you have the ability to withdraw at any time. To be eligible for this clinical trial you must be between 18 – 75 years and have a diagnosis of MDD.

To register interest in this trial, please visit www.researchforyou.co.uk